Candel Therapeutics Past Earnings Performance
Past criteria checks 0/6
Candel Therapeutics's earnings have been declining at an average annual rate of -19.1%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 40.8% per year.
Key information
-19.1%
Earnings growth rate
6.9%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | -40.8% |
Return on equity | n/a |
Net Margin | n/a |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Candel Therapeutics: Innovative Cancer Therapies, But Short Cash Runway
Jul 01Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer
Apr 15Candel gets European orphan drug designation for brain, spinal cord tumor treatment
Sep 15Candel Therapeutics appoints CFO, chief medical officer
Sep 07Candel Therapeutics: Next-Generation Oncolytic Viral Immunotherapies
Oct 21Revenue & Expenses Breakdown
How Candel Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 0 | -52 | 14 | -4 |
30 Jun 24 | 0 | -50 | 14 | 0 |
31 Mar 24 | 0 | -37 | 14 | 0 |
31 Dec 23 | 0 | -38 | 14 | 0 |
30 Sep 23 | 0 | -32 | 14 | 16 |
30 Jun 23 | 0 | -32 | 15 | 0 |
31 Mar 23 | 0 | -27 | 15 | 0 |
31 Dec 22 | 0 | -19 | 15 | 0 |
30 Sep 22 | 0 | -12 | 16 | 0 |
30 Jun 22 | 0 | -20 | 15 | 0 |
31 Mar 22 | 0 | -33 | 13 | 0 |
31 Dec 21 | 0 | -36 | 11 | 0 |
30 Sep 21 | 0 | -48 | 10 | 3 |
30 Jun 21 | 0 | -35 | 8 | 8 |
31 Mar 21 | 0 | -20 | 7 | 8 |
31 Dec 20 | 0 | -18 | 6 | 8 |
31 Dec 19 | 0 | -8 | 3 | 0 |
Quality Earnings: CADL is currently unprofitable.
Growing Profit Margin: CADL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CADL is unprofitable, and losses have increased over the past 5 years at a rate of 19.1% per year.
Accelerating Growth: Unable to compare CADL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CADL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: CADL's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.